Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Geekom's A9 Max is an intriguing mini PC, packing in AMD's potent Ryzen AI 9 hx 370 processor, along with the Radeon 890M iGPU. That sits alongside 2TB of NVMe storage and 32GB of DDR5 memory, all ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results